 "Biocon Q3 net profit zooms over two-fold to Rs 217.2 cr on biologics bizz")
Biotechnology major Biocon on Thursday reported over two-fold jump in consolidated net profit to Rs 217.2 crore for the third quarter ended December 2018, mainly on account of the strong performance of its biologics business.
The company had posted a net profit of Rs Rs 91.9 crore for the corresponding period of the previous fiscal, Biocon said in a filing to the BSE.
Its consolidated revenue from operations stood at Rs 1,540.8 crore for the quarter, against Rs 1,057.9 crore, it added.
Shares of Biocon Ltd closed at Rs 670.55 per scrip on the BSE, up 0.04 per cent from the previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app